Beta Nerve Growth Factor (Beta NGF or NGF) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Beta Nerve Growth Factor (Beta NGF or NGF) – Pipeline Review, H2 2016’, provides in depth analysis on Beta Nerve Growth Factor (Beta NGF or NGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)

The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

Astellas Pharma Inc.

Chiesi Farmaceutici SpA

Fujimoto Pharmaceutical Corporation

Krenitsky Pharmaceuticals Inc.

MedImmune, LLC

NsGene A/S

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Staidson (Beijing) Biopharmaceuticals Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Beta Nerve Growth Factor (Beta NGF or NGF) Overview 7

Therapeutics Development 8

Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Stage of Development 8

Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Therapy Area 9

Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Indication 10

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Beta Nerve Growth Factor (Beta NGF or NGF) - Products under Development by Companies 13

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development 22

Amgen Inc. 22

Astellas Pharma Inc. 23

Chiesi Farmaceutici SpA 24

Fujimoto Pharmaceutical Corporation 25

Krenitsky Pharmaceuticals Inc. 26

MedImmune, LLC 27

NsGene A/S 28

Pfizer Inc. 29

Regeneron Pharmaceuticals, Inc. 30

Staidson (Beijing) Biopharmaceuticals Co., Ltd. 31

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles 32

AS-288640100 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

fasinumab - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

fulranumab - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Gene Therapy to Activate NGF for Undisclosed Indication - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

KP-544 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MEDI-7352 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NsG-0202 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

RBM-004 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule for Neurotrophic Keratitis - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

tanezumab - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Projects 49

Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products 51

Beta Nerve Growth Factor (Beta NGF or NGF) - Featured News & Press Releases 52

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain 52

Mar 31, 2016: Janssen Announces Discontinuation of Fulranumab Phase 3 Development Program in Osteoarthritis Pain 53

Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab 53

Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors 53

Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 54

Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug 55

Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program 55

Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab 55

May 12, 2010: Regeneron Provides Initial Data On REGN475 56

Feb 16, 2010: Pending Results of Phase Ib Trial for Nsg0202 for Alzheimer's Disease in 2010 56

Nov 15, 2008: Nsgene Has Announced That Six Patients with Alzheimer's Disease Have Now Been Implanted with Its Novel Biodelivery Product Nsg 0202 57

Oct 24, 2008: Krenitsky Pharmaceuticals Wants Out Of Deal With Keryx 57

Dec 17, 2007: NsGene First To Implant Genetically Modified Cells Into Patients' Brains 58

Dec 12, 2007: Nsgene A/S Begins Phase Ib Clinical Trial with Nsg0202 for the Treatment of Alzheimer’s Disease 59

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Amgen Inc., H2 2016 22

Pipeline by Astellas Pharma Inc., H2 2016 23

Pipeline by Chiesi Farmaceutici SpA, H2 2016 24

Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016 25

Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016 26

Pipeline by MedImmune, LLC, H2 2016 27

Pipeline by NsGene A/S, H2 2016 28

Pipeline by Pfizer Inc., H2 2016 29

Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016 30

Pipeline by Staidson (Beijing) Biopharmaceuticals Co., Ltd., H2 2016 31

Dormant Projects, H2 2016 49

Dormant Projects (Contd..1), H2 2016 50

Discontinued Products, H2 2016 51

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports